Verzögert
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
3.55 USD | -10.80% | +32.67% | -.--% |
Kurzporträt
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Chief Executive Officer | 53 | 01.01.17 | |
Thomas Schuetz
FOU | Founder | 63 | 01.01.14 |
Neil Lerner
DFI | Director of Finance/CFO | 56 | 01.01.20 |
Karin Herrera
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.23 |
Minori Rosales
CTO | Chief Tech/Sci/R&D Officer | 61 | 01.05.23 |
General Counsel | - | 01.08.21 | |
Ian Chia
PRN | Corporate Officer/Principal | - | 01.01.18 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Richard Lindahl
BRD | Director/Board Member | 70 | 21.04.23 |
Mary Gray
BRD | Director/Board Member | 71 | 25.04.22 |
Ellen Chiniara
BRD | Director/Board Member | 65 | 25.04.22 |
Carl Gordon
CHM | Chairman | 59 | 01.01.15 |
Phil Ferneau
BRD | Director/Board Member | 62 | 01.01.15 |
Thomas Schuetz
FOU | Founder | 63 | 01.01.14 |
James Boylan
BRD | Director/Board Member | 57 | 01.11.22 |
Chief Executive Officer | 53 | 01.01.17 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 137 589 171 | 119 101 964 ( 86,56 %) | 0 | 86,56 % |
Unternehmenskontakt
Sektor
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
-1.17% | 104 Mrd. | |
+2.87% | 97.47 Mrd. | |
+3.32% | 22.25 Mrd. | |
-14.77% | 21.68 Mrd. | |
-7.89% | 18.2 Mrd. | |
-39.98% | 17.02 Mrd. | |
-13.21% | 16.36 Mrd. | |
+8.55% | 14.39 Mrd. | |
+35.75% | 12.37 Mrd. |
- Börse
- Aktien
- A2QF3P Aktie
- A2QF3P Aktie
- Unternehmen Compass Therapeutics, Inc.